First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset Pompe disease.

No abstract is available for this paper.

• Publication year

  2022

• Venue

  medRxiv

• Publication date

  2022-12-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1101/2022.12.22.22283398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease

  2022cited by this paper
• Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.

  2021cited by this paper
• Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus

  2021cited by this paper
• STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa

  2021cited by this paper
• Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.

  2020cited by this paper
• Effects of immunomodulation in classic infantile Pompe patients with high antibody titers

  2019cited by this paper
• High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy

  2018cited by this paper
• Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

  2018cited by this paper
• Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant

  2017cited by this paper
• Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study

  2016cited by this paper
• Pompe disease gene therapy.

  2011cited by this paper
• Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

  2009cited by this paper
• Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

  2008cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Pompe's disease.

  2000cited by this paper

• Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy

  2024influential citation
• Pompe disease: Unmet needs and emerging therapies.

  2024cites this paper